NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Managed Health Care Sector Outlook — September 2026

A sector-wide look at managed health care valuation and deal activity, comparing scaled carriers with risk-bearing care delivery. Built for owners, boards and management teams weighing pricing, growth and business-mix choices heading into the next bid cycle.

For information only. Not an appraisal or a fairness opinion.

What moved since: Managed Health Care M&A update, 14–28 September 2026

Key figures

Premium-end P/E (CY2027E)
43.4x
vs 11.1x at the discount end
Discount-end P/E (CY2027E)
11.1x
vs 43.4x at the premium end
Sector median P/E (CY2027E)
19.4x
all 8 rated companies
Care-delivery share of peer set
25%
vs 75% carriers

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE

Managed Health Care: Premiums Sit with Durability

The peer set rewards credible earnings durability across both scaled carriers and risk-bearing care delivery.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis P / E (CY2027E)

Managed Health Care Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Managed health care splits between scaled carriers and risk-bearing care delivery, with premiums spanning both models. The premium end trades at 43.4x forward earnings versus 11.1x at the discount end, a gap that persists even after forecast growth is credited. Faster-growing peers carry only a modest rating edge, keeping underwriting margin and benefit-ratio discipline central to the value story. Precedent transactions confirm strategic and sponsor interest reaches both regulated risk-bearing assets and adjacent services.

Key findings

  • Premium end trades at 43.4x versus 11.1x at the discount end
  • Care delivery is 25% of the peer set; carriers are the other 75%
  • Faster-growing peers rate at 19.4x versus 17.6x for slower growth
  • Only 3 of 8 peer companies clear both growth and margin bars

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE

    Cover page introducing the Managed Health Care sector outlook dated September 2026.

    We open with the sector's defining split: scaled carriers versus risk-bearing care delivery, both priced on forward earnings as of September 2026. This sets up the valuation and transaction evidence that follows.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE Managed Health Care: Premiums Sit with Durability The peer set rewards credible earnings durability across both scaled carriers and risk-bearing care delivery. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis P / E (CY2027E) Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the report's five sections plus appendix.

    We walk through five sections plus an appendix, starting with the bottom line so the full story lands in the first section. Everything after that — the landscape, valuation, precedent transactions and strategic implications — builds the evidence behind it.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Managed Health Care Rewards Durable Earnings Across Two Distinct Operating Models 02 The Landscape Risk-Bearing Care Delivery Carries a Higher Rating than the Carrier Group 03 Valuation & Situations The Valuation Range Leaves Room for Operating Proof to Matter 04 Precedent Transactions Precedent Transactions Span Plans, Services and Care Infrastructure 05 Strategic Implications Durable Underwriting Proof Strengthens Strategic Standing 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Managed Health Care Splits Between Scaled Carriers and Risk-Bearing Care Delivery, with Premiums Spanning Both

    Summary slide stating that managed health care splits between scaled carriers and risk-bearing care delivery, with premiums spanning both.

    We size the full story here: premiums stretch across both the carrier and care-delivery models, not just one. The valuation basis is forward P/E on CY2027E consensus, validated across all 8 rated companies, so what follows is built on the industry's own pricing convention. That gives us a clean, apples-to-apples read on where durability is being rewarded.

    Everything on this page

    01 · THE BOTTOM LINE Managed Health Care Splits Between Scaled Carriers and Risk-Bearing Care Delivery, with Premiums Spanning Both The full story on one page · figures on P / E (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (8 of 8 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Premium End Reflects a High Bar for Durability The premium end sits at 43.4x versus 11.1x at the discount end. Forward P / E already credits forecast earnings growth, so the surviving gap points to confidence in earnings durability. 2 Faster Growth Sits Alongside a Higher Rating The faster-growing four names in the peer set sit at 19.4x, versus 17.6x for the slower-growing four. The modest spread keeps benefit ratio control and bid-cycle execution central to the equity story. 3 Care Delivery Adds a Distinct Route to Value Risk-bearing care delivery represents 25% of the peer set, while multi-line health plan carriers represent 75%. Direct influence over attributed lives and medical cost gives the smaller segment a different operating proposition. 4 Few Names Combine Growth with Margin Only 3 of 8 names in the peer set clear both growth and margin bars. That concentration keeps attention on PMPM economics, risk adjustment and the conversion of membership growth into earnings. 19.4x Sector median P/E CY2027E consensus · 8 rated of 8 companies 43.4x Premium end P/E vs 11.1x at the discount end top quartile (n=2) against bottom quartile (n=2) on P/E — the spread the report explains 12 Transactions with disclosed terms 43 recorded in this tier · 0 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market landscape section.

    We turn now to the market map — how the peer set splits between carrier scale and care-delivery accountability. Risk-bearing care delivery carries a higher rating than the carrier group, a distinction worth holding onto through the rest of this section.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Risk-Bearing Care Delivery Carries a Higher Rating than the Carrier Group The smaller segment pairs care delivery with direct accountability for medical cost. 02 of 06 Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Managed Health Care Divides Between Carrier Scale and Care-Delivery Accountability

    Chart grouping the 8 approved companies by business segment with median forward P/E per group.

    We group all 8 approved companies into their business segments and take the median forward P/E in each. The split shows carrier scale sitting alongside a smaller, higher-rated care-delivery group. That contrast frames the segment-level valuation story on the next page.

    Everything on this page

    02 · MARKET MAP Managed Health Care Divides Between Carrier Scale and Care-Delivery Accountability 8 approved companies grouped by business segment · median P / E (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 MULTI-LINE HEALTH PLAN CARRIERS 6 cos median 19.4x CVS Health (CVS) Humana (HUM) Centene (CNC) Molina Healthcare (MOH) Clover Health (CLOV) Alignment (ALHC) Carrier platforms bring membership scale, regulated capital and exposure to recurring bid and rate cycles. RISK-BEARING CARE DELIVERY (PAYVIDER CLINIC NETWORKS) 2 cos median 30.8x Astrana Health (ASTH) Agilon Health (AGL) Care-delivery networks pair clinical infrastructure with delegated or full-risk accountability for medical cost.

  6. 06
    02 · LANDSCAPE

    The Smaller Care-Delivery Segment Carries the Higher Valuation

    Segment view showing the smaller care-delivery segment carries the higher median valuation.

    The smaller care-delivery segment — 25% of the peer set — carries the higher median valuation, while carriers at 75% anchor the base. Direct accountability for medical cost appears to be the distinguishing feature the market is pricing here. We treat this as an association worth watching, not a proven cause.

    Everything on this page

    02 · LANDSCAPE The Smaller Care-Delivery Segment Carries the Higher Valuation Segment view of the approved universe · P / E (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median P/E Names to know What they do — and why it matters Multi-line health plan carriers 6 75% 19.4x CVS Health Corp. (CVS) · Humana Inc. (HUM) · +4 more Scale meets regulated risk. This group represents 75% of the peer set. Its standing rests on pricing discipline, Star Ratings, statutory capital and consistent management of the benefit ratio. Risk-bearing care delivery (payvider clinic networks) 2 25% 30.8x Astrana Health, Inc. (ASTH) · Agilon Health, Inc. (AGL) Care ownership changes accountability. This group represents 25% of the peer set and sits at 30.8x. Its model links attributed lives, clinical execution and medical-cost performance more directly.

  7. 07
    SECTION 03

    03

    Section divider introducing the valuation and situations section.

    We move into valuation next: how forward P/E separates the premium and discount ends, even once forecast earnings growth is credited. That leaves room for operating proof to keep mattering.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Valuation Range Leaves Room for Operating Proof to Matter Forward P / E separates the premium and discount ends even after forecast earnings growth is credited. 03 of 06 Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Premium End Sustains a Wide Lead on Forward Earnings

    Bar chart of forward P/E across all 8 rated companies sorted descending, against a sector median.

    Across all 8 rated companies, the premium end sustains a wide lead at 43.4x against a sector median of 19.4x. The tier zones split the rated set at its own quartiles, so the spread we're showing is drawn directly from this peer set. That persistent gap even after credit for forecast growth is the clearest evidence of a durability premium.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Premium End Sustains a Wide Lead on Forward Earnings P / E (CY2027E) · all 8 rated companies, sorted descending · sector median 19.4x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: P / E on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (8 of 8 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same P / E (CY2027E) basis. Panel commentary is a NeuraCap view. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 43.4x CORE · median 19.4x DISCOUNT · median 11.1x Sector median 19.4x WHAT SEPARATES THE TWO ENDS The range remains wide. The premium end sits at 43.4x, while the discount end sits at 11.1x. Forecast growth is already credited. Because the lens is CY2027E P / E, the gap that remains is associated with confidence in the durability of forecast earnings. Operating models cross the tiers. Agilon Health, Inc. [AGL] and Clover Health Investments, Corp. [CLOV] reach the premium end through different models, while Centene Corp. [CNC] and CVS Health Corp. [CVS] sit at the discount end.

  9. 09
    03 · VALUATION DRIVERS

    Faster Growth Carries a Modest Premium, Leaving Earnings Quality in Focus

    Median forward P/E compared across revenue-growth and EBITDA-margin cohorts within the rated set.

    The faster-growing four names sit at 19.4x versus 17.6x for the slower four — a real but modest premium for growth. We read this as an association in the data, not a causal claim. It keeps earnings quality, not just growth, at the center of the equity story.

    Everything on this page

    03 · VALUATION DRIVERS Faster Growth Carries a Modest Premium, Leaving Earnings Quality in Focus Median P / E (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=4; higher-margin n=4; lower-margin n=4). Driver readings are NeuraCap views on the supplied data — association, not causation. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 P/E, median per cohort · growth split at 8% · EBITDA-margin split at 3% Growth Above the Split Carries the Higher Rating Among the four names at or above 8% growth, the middle valuation is 19.4x, versus 17.6x for the four below the split. Underwriting Durability Remains the Commercial Test The narrow growth-based spread keeps the quality of bid pricing, benefit ratio control and reserve development central to how forecast earnings are judged. Care-Model Economics Add Another Distinction Owned or tightly aligned care delivery can change the relationship between capitation, clinical execution and medical cost, but the peer set shows that structure alone does not define the tier.

  10. 10
    03 · SITUATION MAP

    The Peer Set Shows Four Distinct Growth and Valuation Positions

    Two-by-two map cutting the peer set on P/E versus the sector median and revenue growth versus the covered median.

    We cut the peer set on valuation against the 19.4x sector median and growth against the covered median, producing four distinct situations. These boundaries describe where each company sits today; they are observations, not recommendations. The pattern helps frame the strategic choices on the following pages.

    Everything on this page

    03 · SITUATION MAP The Peer Set Shows Four Distinct Growth and Valuation Positions Cut on P / E vs the sector median (19.4x) (rows) and revenue growth vs the covered median (8%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Growth, Higher Valuation Above-median multiple · above-median revenue growth 2 names Molina Healthcare, Inc. (MOH) · Clover Health Investments, Corp. (CLOV) Molina Healthcare, Inc. [MOH] and Clover Health Investments, Corp. [CLOV] pair above-range growth with above-range valuation. Their position puts forecast earnings delivery and retention of growth in focus. Lower Growth, Higher Valuation Above-median multiple · below-median revenue growth 2 names Humana Inc. (HUM) · Agilon Health, Inc. (AGL) Humana Inc. [HUM] and Agilon Health, Inc. [AGL] carry above-range valuation alongside below-range growth. The premium sits alongside expectations for earnings durability beyond current top-line expansion. Higher Growth, Lower Valuation Below-median multiple · above-median revenue growth 2 names Astrana Health, Inc. (ASTH) · Alignment Healthcare, Inc. (ALHC) Astrana Health, Inc. [ASTH] and Alignment Healthcare, Inc. [ALHC] pair above-range growth with below-range valuation. Their position highlights the importance of converting growth into durable margin and cash earnings. Lower Growth, Lower Valuation Below-median multiple · below-median revenue growth 2 names CVS Health Corp. (CVS) · Centene Corp. (CNC) CVS Health Corp. [CVS] and Centene Corp. [CNC] sit below both reference lines. Improvement in pricing, mix or medical-cost performance would change how this position is assessed.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Only a Minority of the Peer Set Clears Both Operating Bars

    Scatter of revenue growth against EBITDA margin for 8 companies with median P/E by quadrant.

    Cutting the peer set at the covered medians of 8% growth and 3% margin, only 3 of 8 names clear both bars at once. That concentration is exactly why PMPM economics and margin conversion stay central to how the market prices growth. It is a clear signal of where the bar sits for durable earnings proof.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Only a Minority of the Peer Set Clears Both Operating Bars Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 8 companies with both estimates · cuts at the covered medians (8% growth, 3% margin) · median P/E per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful P/E (balanced n=3; margin-only n=1; growth-only n=1; neither n=3). Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 10% 20% 2% 4% 6% MARGIN ONLY median 10.3x BALANCED median 19.3x NEITHER median 23.3x GROWTH ONLY median 19.5x CNC CVS HUM AGL MOH ASTH CLOV ALHC x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS The chart compares revenue growth with margin across the eight-name peer set. Astrana Health, Inc. [ASTH], Clover Health Investments, Corp. [CLOV] and Alignment Healthcare, Inc. [ALHC] clear both the 8% growth bar and the 3% margin bar. One name clears only the margin bar, one clears only the growth bar and three clear neither. The pattern shows why growth and current profitability need to be read together. The balanced median rests on 3 names and is lifted by CLOV at 43.1x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 0 of 8 names clear it.

  12. 12
    03 · THE AGENDA

    The Strategic Choice Is Whether to Build Durable Earnings Proof in Underwriting Margin or in Premium Growth

    Framing page posing the strategic choice between underwriting-margin proof and premium-growth proof.

    We frame the core strategic choice the data raises: build durable earnings proof through underwriting margin, or through premium growth. This is a NeuraCap view grounded in the cohort evidence just shown, not a recommendation on any specific security. It sets up the strategic implications we cover later in the report.

    Everything on this page

    03 · THE AGENDA The Strategic Choice Is Whether to Build Durable Earnings Proof in Underwriting Margin or in Premium Growth NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Protect Underwriting Economics Prioritise pricing discipline, medical-cost management and risk score accuracy where forecast earnings depend on benefit ratio stability. What changes the answer: The answer changes when cost trend, reserve development or rate adequacy moves outside the assumptions embedded in the bid. Deepen Care-Delivery Alignment Test whether owned, delegated or contracted care models offer the clearest path to better PMPM economics and clinical control. What changes the answer: The answer changes when attributed lives, provider performance or downside-risk exposure alters the economics of ownership. Refine Revenue Quality and Mix Concentrate growth in products and markets where retention, Star Ratings and contract durability support repeatable earnings. What changes the answer: The answer changes when membership growth brings adverse selection, concentration or re-procurement risk. Choose Build Versus Buy Carefully Compare internal investment with partnerships or acquisitions across care delivery, enablement and risk-bearing capabilities. What changes the answer: The answer changes when regulatory approval, statutory capital or integration demands outweigh the operating benefit.

  13. 13
    SECTION 04

    04

    Section divider introducing the precedent transactions section.

    We shift to the deal record next: precedent transactions that span plans, services and care infrastructure. Strategic and sponsor activity reaches both regulated risk-bearing assets and adjacent services.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Span Plans, Services and Care Infrastructure Strategic and sponsor activity reaches both regulated risk-bearing assets and adjacent services. 04 of 06 Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    The Transaction Record Reaches Across Plans, Services and Care Infrastructure

    Three case studies drawn from twelve disclosed-terms transactions, with multiples on LTM financials at announcement.

    We highlight 3 of the 12 disclosed-terms transactions as case studies, each priced on LTM financials at announcement. These deal multiples sit on a different basis than the CY2027E public multiples shown earlier, so we don't draw a spread between them. The record itself shows buyers reaching across plans, services and care infrastructure — the full list sits in the appendix.

    Everything on this page

    04 · DEAL CASE STUDIES The Transaction Record Reaches Across Plans, Services and Care Infrastructure 3 of 12 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 46 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 31 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Sep-2015 n/a Molina Healthcare, Inc. acquires Providence Human Services, LLC and Providence Community Services, LLC EV / LTM revenue n/a EV / LTM EBITDA 9.8x WHY THE DEAL HAPPENED Molina Healthcare, Inc. moved for Providence Human Services, LLC and Providence Community Services, LLC in Sep-2015; the record shows it as announced. HOW THE TARGET WAS VALUED Terms were not fully disclosed; the transaction anchors the reference set rather than the price. Jul-2012 n/a WellPoint, Inc. acquires AmeriGroup Corporation EV / LTM revenue 12.3x EV / LTM EBITDA 12.3x WHY THE DEAL HAPPENED WellPoint, Inc. moved for AmeriGroup Corporation in Jul-2012; the record shows it as announced. HOW THE TARGET WAS VALUED Terms were not fully disclosed; the transaction anchors the reference set rather than the price. Oct-2011 n/a Cigna Corporation acquires HealthSpring, Inc. EV / LTM revenue 7.6x EV / LTM EBITDA 7.8x WHY THE DEAL HAPPENED Cigna Corporation moved for HealthSpring, Inc. in Oct-2011; the record shows it as announced. HOW THE TARGET WAS VALUED Terms were not fully disclosed; the transaction anchors the reference set rather than the price.

  15. 15
    SECTION 05

    05

    Section divider introducing the strategic implications section.

    We close the analysis with strategic implications: what durable underwriting proof means for standing in this sector. Benefit ratio control, risk adjustment and care-model economics stay central to the value story.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Durable Underwriting Proof Strengthens Strategic Standing Benefit ratio control, risk adjustment and care-model economics remain central to the value story. 05 of 06 Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    The Owner's Next Move Is to Reinforce Durable Underwriting Economics in Pricing and Business Mix

    Page framing the owner's next move as reinforcing durable underwriting economics in pricing and business mix.

    Our view is that the owner's next move is to reinforce durable underwriting economics through pricing and business mix. This is a directional read drawn from the analysis in this report, not a recommendation, but it puts a concrete set of questions on the table for the next twelve months. Owners, management teams and boards each have a distinct angle on it, covered on this page.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS The Owner's Next Move Is to Reinforce Durable Underwriting Economics in Pricing and Business Mix NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Anchor Strategy in Earnings Durability Focus capital and management attention on the products, geographies and care models where pricing discipline and medical-cost control are repeatable. FOR MANAGEMENT TEAMS Convert Growth into Margin Proof Membership expansion carries more weight when PMPM economics, retention and risk adjustment support durable earnings. FOR BOARDS Test Structure Against Strategic Fit Evaluate whether carrier scale, delegated risk or owned care delivery offers the clearest route to resilience through bid, rate and quality cycles.

  17. 17
    SECTION 06

    06

    Section divider introducing the appendix of comparables, transactions and methodology.

    We close with the full universe: every comparable, every precedent transaction and the methodology behind the figures shown earlier. This is where a client can trace any number back to its underlying source.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on P / E (CY2027E), Grouped by Valuation Tier

    Full table of all 8 rated companies' forward P/E, grouped by valuation tier against the sector median.

    All 8 rated companies appear here, shaded against the 19.4x sector median, with tickers linking to the underlying source. This is the complete comparable set behind every valuation figure shown in the body. Use it to check any single-name multiple against the group it sits in.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on P / E (CY2027E), Grouped by Valuation Tier Teal shading marks a P/E above the sector median (19.4x); amber marks below · 8 rated companies · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 8 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV P/E (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥28.3x · median 43.4x · 2 companies Agilon Health, Inc. AGL Risk-bearing care delivery (payvider clinic networks) $1.1B 43.7x 7% 2% 10 Clover Health Investments, Corp. CLOV Multi-line health plan carriers $2.1B 43.1x 20% 4% 24 CORE — 16.4x–28.3x · median 19.4x · 4 companies Humana Inc. HUM Multi-line health plan carriers $38.9B 23.3x 3% 2% 6 Molina Healthcare, Inc. MOH Multi-line health plan carriers $4.6B 19.5x 8% 2% 10 Alignment Healthcare, Inc. ALHC Multi-line health plan carriers $1.2B 19.3x 25% 3% 28 Astrana Health, Inc. ASTH Risk-bearing care delivery (payvider clinic networks) $2.6B 17.9x 10% 7% 17 DISCOUNT — <16.4x · median 11.1x · 2 companies Centene Corp. CNC Multi-line health plan carriers $23.6B 11.9x -1% 2% 0 CVS Health Corp. CVS Multi-line health plan carriers $179B 10.3x 3% 5% 8

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Table of the precedent transactions with disclosed terms, newest first.

    This page lists the disclosed-terms transactions behind the case studies, newest first, with deal values linking to the underlying filing. Multiples here are LTM at announcement, a different basis from the CY2027E public multiples used elsewhere. It's the full evidentiary record behind the transaction narrative.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 12 transactions with disclosed terms in this tier (43 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 46 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 31 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Oct-2020 Social Capital Hedosophia Holdings Corp. III → Clover Health Investments, Corp. $596M n/a n/a Social Capital Hedosophia Holdings Corp. III agreed to combine with Clover Health Investments, Corp. [CLOV]. The recorded value is $596M and serves as a filing reference rather than an operating valuation benchmark. Apr-2020 Beretta Holding S.A. → NextLevel Health Partners, Inc. n/a n/a 4.9x Beretta Holding S.A. agreed to acquire NextLevel Health Partners, Inc. The recorded 4.9x EV / EBITDA multiple provides an earnings benchmark for a health-plan transaction. Sep-2017 SS&C Technologies Holdings, Inc. → New Mexico Health Connections n/a 6.8x 19.4x SS&C Technologies Holdings, Inc. agreed to acquire New Mexico Health Connections. The recorded 6.8x EV / revenue multiple benchmarks the transaction on top-line scale. May-2016 Hellman & Friedman / Leonard Green → MultiPlan Corporation n/a n/a 11.5x Hellman & Friedman / Leonard Green agreed to acquire MultiPlan Corporation. The 11.5x EV / EBITDA benchmark sits alongside sponsor ownership of a services-oriented asset. Sep-2015 Molina Healthcare, Inc. → Providence Human Services, LLC and Providence Community Services, LLC n/a n/a 9.8x Molina Healthcare, Inc. [MOH] agreed to acquire Providence Human Services, LLC and Providence Community Services, LLC. The recorded 9.8x EV / EBITDA multiple provides an earnings benchmark for adjacent services. Apr-2013 Roper Industries, Inc. → Managed Health Care Associates, Inc. n/a 0.7x 8.8x Roper Industries, Inc. agreed to acquire Managed Health Care Associates, Inc. The transaction was recorded at 0.7x EV / revenue and 8.8x EV / EBITDA. Jul-2012 WellPoint, Inc. → AmeriGroup Corporation n/a 12.3x 12.3x WellPoint, Inc. agreed to acquire AmeriGroup Corporation. The transaction was recorded at 12.3x on both the EV / revenue and EV / EBITDA measures. Oct-2011 Cigna Corporation → HealthSpring, Inc. n/a 7.6x 7.8x Cigna Corporation agreed to acquire HealthSpring, Inc. The transaction was recorded at 7.6x EV / revenue and 7.8x EV / EBITDA. Mar-2007 UnitedHealth Group, Inc. → Sierra Health Services, Inc. n/a n/a 11.1x UnitedHealth Group, Inc. agreed to acquire Sierra Health Services, Inc. The transaction illustrates strategic interest in regulated membership and carrier infrastructure.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    Continuation of the full precedent transaction table, newest first.

    We continue the same transaction list here, preserving the newest-first order and the LTM-at-announcement basis. Together with the prior page, this is the complete disclosed-terms record supporting the deal narrative. It closes out the transaction evidence a client can trace deal by deal.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 12 transactions with disclosed terms in this tier (43 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 46 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 31 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jul-2005 UnitedHealth Group, Inc. → PacifiCare Health Systems, Inc. n/a n/a 15.8x Oct-2003 Anthem Inc. → WellPoint Health Networks Inc. n/a n/a 10.7x Oct-2003 UnitedHealth Group, Inc. → Mid Atlantic Medical Services LLC n/a n/a 10.6x

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Page setting out the report's sources, assumptions and data-quality treatment.

    This page sets out the valuation basis, the underlying sources and how data-quality exceptions were handled across the comparable and transaction sets. It shows what was included, what was excluded, and on what basis each figure was read. It's the reference point for tracing any individual figure back to where it came from.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Managed Health Care Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: P / E on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (8 of 8 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Managed Health Care and it clears the coverage gate with 8 of 8 companies (100%). EV / Revenue is carried as a cross-check. DATA QUALITY & EXCLUSIONS 9 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 318 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (317) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    The Premium Sits with Credible Durability Across Both Managed-Care Models.

    Closing slide restating that the premium sits with credible durability across both managed-care models.

    We close where we started: the premium sits with credible durability across both managed-care models, carriers and care delivery alike. The companion tables carry the full universe and source index for any figure a client wants to trace further.

    Everything on this page

    The Premium Sits with Credible Durability Across Both Managed-Care Models. NeuraCap AI — Managed Health Care Coverage September 2026 · Prepared by NeuraCap AI · Confidential Managed Health Care Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Managed Health Care (Health Care › Health Care Equipment and Services › Managed Health Care) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Managed Health Care according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Agilon Health, Inc. (AGL), Alignment Healthcare, Inc. (ALHC), Astrana Health, Inc. (ASTH), Clover Health Investments, Corp. (CLOV), Centene Corp. (CNC), CVS Health Corp. (CVS), Humana Inc. (HUM), Molina Healthcare, Inc. (MOH). The market map groups them by business vertical — Multi-line health plan carriers: 6 companies (CVS, HUM, CNC, MOH, CLOV, ALHC); Risk-bearing care delivery (payvider clinic networks): 2 companies (ASTH, AGL). 8 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Managed Health Care (Health Care › Health Care Equipment and Services › Managed Health Care) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Managed Health Care according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Agilon Health, Inc. (AGL), Alignment Healthcare, Inc. (ALHC), Astrana Health, Inc. (ASTH), Clover Health Investments, Corp. (CLOV), Centene Corp. (CNC), CVS Health Corp. (CVS), Humana Inc. (HUM), Molina Healthcare, Inc. (MOH). The market map groups them by business vertical — Multi-line health plan carriers: 6 companies (CVS, HUM, CNC, MOH, CLOV, ALHC); Risk-bearing care delivery (payvider clinic networks): 2 companies (ASTH, AGL). 8 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

9 records failed a validation gate and never feed a statistic in this report (9 excluded from aggregate). Each exclusion, with its reason: AGL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AGL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLOV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLOV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CNC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: P / E on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on P / E rather than EV / EBITDA; validated coverage supports the industry standard (8 of 8 companies), so this report follows it. P / E on CY2027E is the lead convention: it is the sector-appropriate prior for Managed Health Care and it clears the coverage gate with 8 of 8 companies (100%). EV / Revenue is carried as a cross-check. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 8 of 8 companies; EV / rEVenue: 8 of 8 companies; P/E: 8 of 8 companies.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥28.3x, Core 16.4x–28.3x, Discount <16.4x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 19.4x = median(pe_ratio CY2027E) (8 rated companies) · 43.4x = median(pe_ratio CY2027E) within Premium tier (n=2) · 19.4x = median(pe_ratio CY2027E) within Core tier (n=4) · 11.1x = median(pe_ratio CY2027E) within Discount tier (n=2) · 19.4x = median(pe_ratio CY2027E) | growth ≥ 8% (n=4) · 17.6x = median(pe_ratio CY2027E) | growth < 8% (n=4) · 18.6x = median(pe_ratio CY2027E) | EBITDA margin ≥ 3% (n=4) · 21.4x = median(pe_ratio CY2027E) | EBITDA margin < 3% (n=4) · 10% = median Rule of 40 score (revenue growth + EBITDA margin) (n=8) · 19.3x = median(pe_ratio CY2027E) within balanced quadrant (n=3) · 10.3x = median(pe_ratio CY2027E) within marginOnly quadrant (n=1) · 19.5x = median(pe_ratio CY2027E) within growthOnly quadrant (n=1) · 23.3x = median(pe_ratio CY2027E) within neither quadrant (n=3) · 43.1x = pe_ratio CY2027E for CLOV (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Managed Health Care recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 43 transactions were recorded for this industry; 12 are shown. 31 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 23 × deal value unit unresolved; 13 × no evidence record; 3 × duplicate precedent id; 1 × duplicate filings collapsed; 1 × divestiture roles reassigned; 5 × financial target ev not meaningful. Case studies lead with the 0 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 322 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Managed Health Care?

Company valuation reports run the same method against a single business — public or private.